Table 2.
Clinical response of ocular inflammation to certolizumab pegol treatment.
| Patient No. | Ocular Findings at Start of Certolizumab Treatment |
Ocular Findings at Last Follow-Up with Certolizumab Treatment |
Concomitant Medications at Last Follow-Up | Treatment Duration (months) | ||||
|---|---|---|---|---|---|---|---|---|
| BCVA (OD; OS) | Anterior Segment Inflammationa | Posterior Segment Inflammationb | BCVA (OD; OS) | Anterior Segment Inflammationa | Posterior Segment Inflammationb | |||
| 1 | 20/25; 20/25 | 0.5+ OU | 1+ OD; 0.5+ OS | 20/20; 20/25 | 0 OU | 0 OU | none | 42 |
| 2 | 20/60; 20/50 | 2+ OU | 0 OU | 20/40; 20/50 | 0.5+ OU | 0 OU | difluprednate 0.05%, MTX | 7 |
| 3 | 20/20; 20/30 | 2+ OS | 0 OU | 20/20; 20/20 | 0 OU | 0 OU | difluprednate 0.05% | 48 |
BCVA, best corrected visual acuity; OD, right eye; OS, left eye; OU, both eyes; MTX, methotrexate.
a
Anterior chamber inflammation was graded according to the standardization of uveitis nomenclature (SUN) grading system.18
b
Posterior segment inflammation was graded according to standardization of vitreal inflammatory activity grading scale.19